Last updated
Neobe Therapeutics: Capital Raising
UK biotech Neobe Therapeutics raised $6.8M (£5M) in seed funding led by ARC Ventures, with participation from Faber, Macmillan Ventures, Proven Connect and Empirical Ventures, to advance its NEO22 engineered-bacteria cancer program toward an IND filing in 2028.
Source: Scaling Europe Daily
- Who
- Neobe Therapeutics · Biotech & Pharma · UK
- What happened
- UK biotech Neobe Therapeutics raised $6.8M (£5M) in seed funding led by ARC Ventures, with participation from Faber, Macmillan Ventures, Proven Connect and Empirical Ventures, to advance its NEO22 engineered-bacteria cancer program toward an IND filing in 2028.
- When
- 2026-11-10
- Source
- Scaling Europe Daily
- So what
- Fresh capital is a hiring signal before it is anything else.
The leadership read
Fresh capital is a hiring signal before it is anything else. For Neobe Therapeutics, a raise in Biotech & Pharma funds leadership depth, scale, go-to-market and operational rigour, rather than any single appointment. Watch where Neobe Therapeutics hires first across EMEA; that is where the capital is really pointed.
Market context: The wider read — a Talent Market Index of 97.6 (Neutral), down 3.4 month-on-month — shows EMEA signal flow rising (+5.9pts).
Neobe Therapeutics: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 32 tracked companies.
MitchelLake in this thematic
More signals across Biotech & Pharma
Capital Raising · EMEA
mbiomics →mbiomics secured a further €12M, bringing its Series A to €30M to advance microbiome-based therapeutics (as reported in a roundup of European biotech financings).
Capital Raising · EMEA
SK pharmteco →SK pharmteco announced a $200M+ investment plan over five years to expand CDMO (contract development and manufacturing organization) capabilities and infrastructure.
Leadership Change · EMEA
Harbour BioMed →Harbour BioMed (HKEX: 02142) appointed Vivian Feng as Head of External Collaboration, a new senior role overseeing partnerships with external parties.
Geographic Expansion · EMEA
Bio-Techne →Bio-Techne is expanding its GMP manufacturing network with a new facility in Bristol, UK, to scale cell therapy development capabilities alongside existing North American operations.
Product Launch · EMEA
AviadoBio →AviadoBio has presented Phase 1/2 trial data for AVB-101, its investigational gene therapy for frontotemporal dementia with GRN mutations (FTD-GRN), showing dose-dependent increases in cerebrospinal fluid progranulin levels across four ascending doses.
Product Launch · EMEA
Biogen Inc. →Biogen announced 52-week Phase 2 results for litifilimab in cutaneous lupus erythematosus (CLE), demonstrating rapid and durable efficacy. Data supports potential first-in-class therapy positioning. Results presented at EADV 2026 Congress in Vienna. Ongoing Phase 2/3 AMETHYST study progressing.
Where this lands in our work
- Executive Search →
Capital raised becomes leadership hired — the executive build follows the announcement.
- Startup →
The first three or four executive hires set a startup's trajectory.
- Executive Search: EMEA →
Our EMEA practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗